Europe Biosimilars Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Disease Indication (Cancer, Diabetes, Autoimmune Diseases, and Other Diseases), Drug Class (Granulocyte Colony-Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-Stimulating Agents, and Others), Route of Administration (Intravenous, Subcutaneous, and Others), and End User (Hospitals, Speciality Clinics, Homecare, and Others)
The Europe biosimilars market is expected to grow from US$ 10,188.49 million in 2022 to US$ 56,373.61 million by 2028. It is estimated to grow at a CAGR of 33.0% from 2022 to 2028.
Cost Effectiveness of Biosimilar Drugs is Driving Europe Biosimilars Market
Biosimilars offer potential benefits to every stakeholder in the health system by providing a lower cost but equally effective treatment option such as biologics. During 2017–2018, the National Health Service (NHS) saved US$ 401.10 million by switching from using ten expensive medicines to better value and equally effective alternatives such as biologics, expecting even more savings to be achieved in the future. The potential savings from using biosimilars can also be used to fund other new treatments. The uptake of biosimilars has been slower in the US than the uptake in European Union (EU) countries. The EU is leading in biosimilar approvals, utilization, and cost savings awareness. Most health systems have developed protocols, incentives, and diverse reimbursement and procurement policies to ensure biosimilar to improve potential savings. However, the decision to prescribe or switch to a biological medicine for an individual patient, whether an originator or biosimilar medicine, is taken by the responsible clinician in consultation with the patient and their family/carers.
According to the report on biosimilars by Cardinal Health in 2022, biosimilar treatment options are proven to be as safe and effective as originator biologics. Biosimilars are approved through an abbreviated FDA pathway to expand patient access to high-quality, lower-cost care. As of January 2022, there are 33 FDA-approved biosimilars in the US, 21 commercially available on the market. The market entrance of biosimilars leads to greater competition, thereby lowering costs and increasing the accessibility and affordability of these critical treatments. Therefore, the cost effectiveness of biosimilar drugs fuels the biosimilar market growth.
Europe Biosimilars Market Overview
Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare community. Healthcare professionals can treat more patients with high-quality biologics while reducing spending. For example, in Germany, according to Sandoz, the number of daily therapeutic doses of an anti-TNF medicine increased by 29% (from 17.18 to 22.18 million) after introducing biosimilars in 2022. Due to the huge potential for cost savings, The German Health Ministry introduced a new law to increase the adoption of biosimilars. As few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. Additionally, In Germany, a law passed in 2019 foresees the automatic substitution of biosimilars in pharmacies beginning in 2022, provided the Federal Joint Committee (the highest decision-making body of the self-governance of health insurers and providers) has determined the interchangeability of the medicines in question and the prescribing physician has not explicitly excluded it. Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to grow.
Europe Biosimilars Market Revenue and Forecast to 2028 (US$ Million)
Europe Biosimilars Market Segmentation
The Europe biosimilars market is segmented into disease indication, drug class, route of administration, end user, and country.
Based on disease indication, the biosimilars market is segmented into cancer, diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share in 2022.
The biosimilars market, based on drug class, is segmented into granulocyte colony-stimulating stimulating factors, human growth hormone, insulin, TNF blockers & monoclonal antibodies, erythropoietin-stimulating stimulating agents, and others. The granulocyte colony-stimulating factors segment accounted for the largest share of the market in 2022.
Based on route of administration, the biosimilar market is segmented into intravenous, subcutaneous, and others. The intravenous segment accounted for the largest share of the market in 2022.
The biosimilars market, based on end user, is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment accounted for the largest share of the market in 2022.
Based on country, the Europe biosimilars market is segmented into U.K., Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the market in 2022.
Amgen Inc; Sanofi SA; Biocon Ltd; Eli Lilly and Co; Sandoz AG; Teva Pharmaceutical Industries Ltd; Pfizer Inc; and Dr. Reddy's Laboratories Ltd are the leading companies operating in the Europe biosimilars market.
Cost Effectiveness of Biosimilar Drugs is Driving Europe Biosimilars Market
Biosimilars offer potential benefits to every stakeholder in the health system by providing a lower cost but equally effective treatment option such as biologics. During 2017–2018, the National Health Service (NHS) saved US$ 401.10 million by switching from using ten expensive medicines to better value and equally effective alternatives such as biologics, expecting even more savings to be achieved in the future. The potential savings from using biosimilars can also be used to fund other new treatments. The uptake of biosimilars has been slower in the US than the uptake in European Union (EU) countries. The EU is leading in biosimilar approvals, utilization, and cost savings awareness. Most health systems have developed protocols, incentives, and diverse reimbursement and procurement policies to ensure biosimilar to improve potential savings. However, the decision to prescribe or switch to a biological medicine for an individual patient, whether an originator or biosimilar medicine, is taken by the responsible clinician in consultation with the patient and their family/carers.
According to the report on biosimilars by Cardinal Health in 2022, biosimilar treatment options are proven to be as safe and effective as originator biologics. Biosimilars are approved through an abbreviated FDA pathway to expand patient access to high-quality, lower-cost care. As of January 2022, there are 33 FDA-approved biosimilars in the US, 21 commercially available on the market. The market entrance of biosimilars leads to greater competition, thereby lowering costs and increasing the accessibility and affordability of these critical treatments. Therefore, the cost effectiveness of biosimilar drugs fuels the biosimilar market growth.
Europe Biosimilars Market Overview
Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare community. Healthcare professionals can treat more patients with high-quality biologics while reducing spending. For example, in Germany, according to Sandoz, the number of daily therapeutic doses of an anti-TNF medicine increased by 29% (from 17.18 to 22.18 million) after introducing biosimilars in 2022. Due to the huge potential for cost savings, The German Health Ministry introduced a new law to increase the adoption of biosimilars. As few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. Additionally, In Germany, a law passed in 2019 foresees the automatic substitution of biosimilars in pharmacies beginning in 2022, provided the Federal Joint Committee (the highest decision-making body of the self-governance of health insurers and providers) has determined the interchangeability of the medicines in question and the prescribing physician has not explicitly excluded it. Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to grow.
Europe Biosimilars Market Revenue and Forecast to 2028 (US$ Million)
Europe Biosimilars Market Segmentation
The Europe biosimilars market is segmented into disease indication, drug class, route of administration, end user, and country.
Based on disease indication, the biosimilars market is segmented into cancer, diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share in 2022.
The biosimilars market, based on drug class, is segmented into granulocyte colony-stimulating stimulating factors, human growth hormone, insulin, TNF blockers & monoclonal antibodies, erythropoietin-stimulating stimulating agents, and others. The granulocyte colony-stimulating factors segment accounted for the largest share of the market in 2022.
Based on route of administration, the biosimilar market is segmented into intravenous, subcutaneous, and others. The intravenous segment accounted for the largest share of the market in 2022.
The biosimilars market, based on end user, is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment accounted for the largest share of the market in 2022.
Based on country, the Europe biosimilars market is segmented into U.K., Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the market in 2022.
Amgen Inc; Sanofi SA; Biocon Ltd; Eli Lilly and Co; Sandoz AG; Teva Pharmaceutical Industries Ltd; Pfizer Inc; and Dr. Reddy's Laboratories Ltd are the leading companies operating in the Europe biosimilars market.
1. INTRODUCTION
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Biosimilars Market – by Disease Indication
1.3.2 Europe Biosimilars Market – by Drug class
1.3.3 Europe Biosimilars Market – by Route of Administration
1.3.4 Europe Biosimilars Market – by End User
1.3.5 Europe Biosimilars Market – by Country
2. EUROPE BIOSIMILARS MARKET – KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. EUROPE BIOSIMILARS MARKET – MARKET LANDSCAPE
4.1 Overview
4.2 Europe PEST Analysis
4.3 Expert’s Opinion
5. EUROPE BIOSIMILARS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Prevalence of Chronic Diseases
5.1.2 Cost Effectiveness of Biosimilar Drugs
5.1.3 Rising Approvals of Biosimilars
5.2 Market Restraints
5.2.1 High-Cost Involvement and Complexities in Biosimilar Product Manufacturing
5.3 Market Opportunities
5.3.1 Patent Expiry of Blockbuster Biologics
5.4 Future Trend
5.4.1 Collaborations for Biosimilars and Clinical Trials
5.5 Impact analysis
6. BIOSIMILARS MARKET – EUROPE ANALYSIS
6.1 Europe: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – BY DISEASE INDICATION
7.1 Overview
7.2 Europe Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Diabetes
7.4.1 Overview
7.4.2 Diabetes: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Autoimmune Diseases
7.5.1 Overview
7.5.2 Autoimmune Diseases: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.3 Psoriasis:
7.5.3.1 Overview
7.5.3.2 Psoriasis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.4 Arthritis:
7.5.4.1 Overview
7.5.4.2 Arthritis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.5 Others:
7.5.5.1 Overview
7.5.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Others Disease Indications
7.6.1 Overview
7.6.2 Others Disease Indications: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8. GLOBAL BIOSIMILARS MARKET ANALYSIS AND FORECAST TO 2028 – BY DRUG CLASS
8.1 Overview
8.2 Global Biosimilars Market, by Drug class 2021 & 2028 (%)
8.3 Granulocyte colony-stimulating factors
8.3.1 Overview
8.3.2 Granulocyte colony-stimulating factors Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Insulin
8.4.1 Overview
8.4.2 Insulin Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.5 TNF Blockers and Monoclonal Antibodies
8.5.1 Overview
8.5.2 TNF Blockers and Monoclonal Antibodies Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9. EUROPE BIOSIMILARS MARKET ANALYSIS AND FORECASTS TO 2028 – BY ROUTE OF ADMINISTRATION
9.1 Overview
9.2 Europe Biosimilars Market, by Application 2021 & 2028 (%)
9.3 Intravenous
9.3.1 Overview
9.3.2 Intravenous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Subcutaneous
9.4.1 Overview
9.4.2 Subcutaneous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – BY END USER
10.1 Overview
10.2 Europe Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Specialty Clinics
10.4.1 Overview
10.4.2 Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.5 Homecare
10.5.1 Overview
10.5.2 Homecare: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.6 Other
10.6.1 Overview
10.6.2 Other: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – COUNTRY ANALYSIS
11.1 Overview
11.1.1 Europe: Biosimilars Market, by Country, 2021 & 2028 (%)
11.1.1.1 Germany: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 Germany: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.3 Germany: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.1.3.1 Germany: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.1.4 Germany: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.1.5 Germany: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.1.6 Germany Biosimilars Market, by End User, 2019–2028 (US$ Million)
11.1.1.2 UK: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 UK: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.3 UK: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.2.3.1 UK: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.2.4 UK: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.2.5 UK: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.2.6 UK: Biosimilars Market, by End User, 2019–2028 (US$ Million)
11.1.1.3 France: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 France: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.3 France: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.3.3.1 France: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.3.4 France: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.3.5 France: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.3.6 France: Biosimilars Market, by End User, 2019–2028 (US$ Million)
11.1.1.4 Italy: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.4.1 Overview
11.1.1.4.2 Italy: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.4.3 Italy: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.4.3.1 Italy: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.4.4 Italy: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.4.5 Italy: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.4.6 Italy: Biosimilars Market, by End User, 2019–2028 (US$ Million)
11.1.1.5 Spain: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.5.1 Overview
11.1.1.5.2 Spain: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.5.3 Spain: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.5.3.1 Spain: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.5.4 Spain: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.5.5 Spain: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.5.6 Spain: Biosimilars Market, by End User, 2019–2028 (US$ Million)
11.1.1.6 Rest of Europe: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.6.1 Overview
11.1.1.6.2 Rest of Europe: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.6.3 Rest of Europe: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.6.3.1 Rest of Europe: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.6.4 Rest of Europe: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.6.5 Rest of Europe: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.6.6 Rest of Europe: Biosimilars Market, by End User, 2019–2028 (US$ Million)
12. BIOSIMILARS MARKET – INDUSTRY LANDSCAPE
12.1 Overview
12.2 Growth Strategies in the Biosimilars Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. COMPANY PROFILES
13.1 Amgen Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Sanofi SA
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Biocon Ltd
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Eli Lilly and Co
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Sandoz AG
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Teva Pharmaceutical Industries Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Pfizer Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Dr. Reddy's Laboratories Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
14.2 Glossary of Terms
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Biosimilars Market – by Disease Indication
1.3.2 Europe Biosimilars Market – by Drug class
1.3.3 Europe Biosimilars Market – by Route of Administration
1.3.4 Europe Biosimilars Market – by End User
1.3.5 Europe Biosimilars Market – by Country
2. EUROPE BIOSIMILARS MARKET – KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. EUROPE BIOSIMILARS MARKET – MARKET LANDSCAPE
4.1 Overview
4.2 Europe PEST Analysis
4.3 Expert’s Opinion
5. EUROPE BIOSIMILARS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Prevalence of Chronic Diseases
5.1.2 Cost Effectiveness of Biosimilar Drugs
5.1.3 Rising Approvals of Biosimilars
5.2 Market Restraints
5.2.1 High-Cost Involvement and Complexities in Biosimilar Product Manufacturing
5.3 Market Opportunities
5.3.1 Patent Expiry of Blockbuster Biologics
5.4 Future Trend
5.4.1 Collaborations for Biosimilars and Clinical Trials
5.5 Impact analysis
6. BIOSIMILARS MARKET – EUROPE ANALYSIS
6.1 Europe: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – BY DISEASE INDICATION
7.1 Overview
7.2 Europe Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Diabetes
7.4.1 Overview
7.4.2 Diabetes: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Autoimmune Diseases
7.5.1 Overview
7.5.2 Autoimmune Diseases: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.3 Psoriasis:
7.5.3.1 Overview
7.5.3.2 Psoriasis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.4 Arthritis:
7.5.4.1 Overview
7.5.4.2 Arthritis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.5 Others:
7.5.5.1 Overview
7.5.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Others Disease Indications
7.6.1 Overview
7.6.2 Others Disease Indications: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8. GLOBAL BIOSIMILARS MARKET ANALYSIS AND FORECAST TO 2028 – BY DRUG CLASS
8.1 Overview
8.2 Global Biosimilars Market, by Drug class 2021 & 2028 (%)
8.3 Granulocyte colony-stimulating factors
8.3.1 Overview
8.3.2 Granulocyte colony-stimulating factors Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Insulin
8.4.1 Overview
8.4.2 Insulin Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.5 TNF Blockers and Monoclonal Antibodies
8.5.1 Overview
8.5.2 TNF Blockers and Monoclonal Antibodies Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9. EUROPE BIOSIMILARS MARKET ANALYSIS AND FORECASTS TO 2028 – BY ROUTE OF ADMINISTRATION
9.1 Overview
9.2 Europe Biosimilars Market, by Application 2021 & 2028 (%)
9.3 Intravenous
9.3.1 Overview
9.3.2 Intravenous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Subcutaneous
9.4.1 Overview
9.4.2 Subcutaneous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – BY END USER
10.1 Overview
10.2 Europe Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Specialty Clinics
10.4.1 Overview
10.4.2 Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.5 Homecare
10.5.1 Overview
10.5.2 Homecare: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.6 Other
10.6.1 Overview
10.6.2 Other: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – COUNTRY ANALYSIS
11.1 Overview
11.1.1 Europe: Biosimilars Market, by Country, 2021 & 2028 (%)
11.1.1.1 Germany: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 Germany: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.3 Germany: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.1.3.1 Germany: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.1.4 Germany: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.1.5 Germany: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.1.6 Germany Biosimilars Market, by End User, 2019–2028 (US$ Million)
11.1.1.2 UK: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 UK: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.3 UK: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.2.3.1 UK: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.2.4 UK: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.2.5 UK: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.2.6 UK: Biosimilars Market, by End User, 2019–2028 (US$ Million)
11.1.1.3 France: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 France: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.3 France: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.3.3.1 France: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.3.4 France: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.3.5 France: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.3.6 France: Biosimilars Market, by End User, 2019–2028 (US$ Million)
11.1.1.4 Italy: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.4.1 Overview
11.1.1.4.2 Italy: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.4.3 Italy: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.4.3.1 Italy: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.4.4 Italy: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.4.5 Italy: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.4.6 Italy: Biosimilars Market, by End User, 2019–2028 (US$ Million)
11.1.1.5 Spain: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.5.1 Overview
11.1.1.5.2 Spain: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.5.3 Spain: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.5.3.1 Spain: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.5.4 Spain: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.5.5 Spain: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.5.6 Spain: Biosimilars Market, by End User, 2019–2028 (US$ Million)
11.1.1.6 Rest of Europe: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.6.1 Overview
11.1.1.6.2 Rest of Europe: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.6.3 Rest of Europe: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.6.3.1 Rest of Europe: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.6.4 Rest of Europe: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.6.5 Rest of Europe: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.6.6 Rest of Europe: Biosimilars Market, by End User, 2019–2028 (US$ Million)
12. BIOSIMILARS MARKET – INDUSTRY LANDSCAPE
12.1 Overview
12.2 Growth Strategies in the Biosimilars Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. COMPANY PROFILES
13.1 Amgen Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Sanofi SA
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Biocon Ltd
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Eli Lilly and Co
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Sandoz AG
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Teva Pharmaceutical Industries Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Pfizer Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Dr. Reddy's Laboratories Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Comparison Between Different Drug Developments
Table 2. Germany Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 3. Germany Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 4. Germany Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 5. Germany Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 6. Germany Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. UK Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 8. UK Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 9. UK Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 10. UK Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 11. UK Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 12. France Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 13. France Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 14. France Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 15. France Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 16. France Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 17. Italy Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 18. Italy Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 19. Italy Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 20. Italy Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 21. Italy Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 22. Spain Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 23. Spain Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 24. Spain Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 25. Spain Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 26. Spain Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 27. Rest of Europe Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 28. Rest of Europe Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 29. Rest of Europe Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 30. Rest of Europe Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 31. Rest of Europe Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 32. Recent Inorganic Growth Strategies in the Biosimilars Market
Table 33. Recent Organic Growth Strategies in the Biosimilars Market
Table 34. Glossary of Terms
Table 1. Comparison Between Different Drug Developments
Table 2. Germany Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 3. Germany Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 4. Germany Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 5. Germany Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 6. Germany Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. UK Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 8. UK Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 9. UK Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 10. UK Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 11. UK Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 12. France Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 13. France Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 14. France Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 15. France Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 16. France Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 17. Italy Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 18. Italy Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 19. Italy Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 20. Italy Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 21. Italy Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 22. Spain Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 23. Spain Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 24. Spain Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 25. Spain Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 26. Spain Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 27. Rest of Europe Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 28. Rest of Europe Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 29. Rest of Europe Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 30. Rest of Europe Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 31. Rest of Europe Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 32. Recent Inorganic Growth Strategies in the Biosimilars Market
Table 33. Recent Organic Growth Strategies in the Biosimilars Market
Table 34. Glossary of Terms
LIST OF FIGURES
Figure 1. Europe Biosimilars Market Segmentation
Figure 2. Europe Biosimilars Market, by Country
Figure 3. Europe Biosimilars Market Overview
Figure 4. Cancer Segment Held Largest Share of Type Segment in Europe Biosimilars Market
Figure 5. UK Expected to Show Remarkable Growth During Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. Europe Biosimilars Market Impact Analysis of Drivers and Restraints
Figure 9. Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 10. Europe Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
Figure 11. Cancer: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Diabetes: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Autoimmune Diseases: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Psoriasis: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Arthritis: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Others: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Others Disease Indications: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Global Biosimilars Market, by Drug class 2021 & 2028 (%)
Figure 19. Granulocyte colony-stimulating factors Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Insulin Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. TNF Blockers and Monoclonal Antibodies Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Others Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Europe Biosimilars Market, by Application 2021 & 2028 (%)
Figure 24. Intravenous: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Others: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Europe Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)
Figure 28. Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Homecare: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Other: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Europe: Biosimilars Market, by Key Country – Revenue (2021) (US$ Million)
Figure 33. Germany: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. UK: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. France: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Italy: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. Spain: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. Rest of Europe: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Growth Strategies in the Biosimilars Market
Figure 1. Europe Biosimilars Market Segmentation
Figure 2. Europe Biosimilars Market, by Country
Figure 3. Europe Biosimilars Market Overview
Figure 4. Cancer Segment Held Largest Share of Type Segment in Europe Biosimilars Market
Figure 5. UK Expected to Show Remarkable Growth During Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. Europe Biosimilars Market Impact Analysis of Drivers and Restraints
Figure 9. Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 10. Europe Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
Figure 11. Cancer: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Diabetes: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Autoimmune Diseases: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Psoriasis: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Arthritis: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Others: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Others Disease Indications: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Global Biosimilars Market, by Drug class 2021 & 2028 (%)
Figure 19. Granulocyte colony-stimulating factors Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Insulin Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. TNF Blockers and Monoclonal Antibodies Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Others Drug class: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Europe Biosimilars Market, by Application 2021 & 2028 (%)
Figure 24. Intravenous: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Others: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Europe Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)
Figure 28. Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Homecare: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Other: Europe Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Europe: Biosimilars Market, by Key Country – Revenue (2021) (US$ Million)
Figure 33. Germany: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. UK: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. France: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Italy: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. Spain: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. Rest of Europe: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Growth Strategies in the Biosimilars Market
